› $150,000,000 verdict in personal injury case
GlaxoSmithKline (GSK) has agreed to pay more than $250 million to resolve about 5,500 claims that its type 2 diabetes drug Avandia (rosiglitazone) caused heart attacks and strokes in patients who used the drug. The payout will help GSK avoid the first trial over claims the pharmaceutical giant allowed the drug to be marketed despite reports that the drug was potentially deadly.
Montgomery, AL: Joyce A. says she did not know that Avandia could cause so many health problems, at least she did not know until her doctor took her off Avandia and put her on another drug. Unfortunately, this happened after she was hospitalized two times with severe chest pains. Although she has started to recover since being taken off Avandia, she says she still experiences some pain.
Mark D. is fighting for justice on behalf of his brother, Grant, whose health has gone downhill since he was prescribed Avandia.
